Sarepta Therapeutics (SRPT) Total Debt (2010 - 2026)

Sarepta Therapeutics' Total Debt history runs 17 years deep, the most recent figure standing at $838.2 million for Q1 2026.

• In Q1 2026, Total Debt fell 26.37% year-over-year to $838.2 million; the TTM figure through Mar 2026 stood at $838.2 million (down 26.37% YoY), while the FY2025 annual figure was $829.0 million, down 27.1% from the prior year.
• Total Debt was $838.2 million for Q1 2026 at Sarepta Therapeutics, up from $829.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.5 billion in Q4 2022 to a low of $829.0 million in Q4 2025.
• Historically, Total Debt has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Debt surged 40.9% in 2022, then decreased 27.1% in 2025.
• A 5-year view of Total Debt shows it stood at $1.5 billion in 2022, then slipped by 19.83% to $1.2 billion in 2023, then fell by 8.15% to $1.1 billion in 2024, then declined by 27.1% to $829.0 million in 2025, then advanced by 1.11% to $838.2 million in 2026.
• The last three Total Debt figures came in at $838.2 million (Q1 2026), $829.0 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.